Abstract | OBJECTIVE: METHODS: Eighty-two patients (50 with RA, 32 with AS) aged 17-77 years were enrolled. All patients were treated with intravenous infliximab. Lipid profile was assessed at baseline and after 6 months of treatment. RESULTS: CONCLUSION:
|
Authors | Dimitrios N Kiortsis, Anastasios K Mavridis, Theodosios D Filippatos, Spyros Vasakos, Spyros N Nikas, Alexandros A Drosos |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 33
Issue 5
Pg. 921-3
(May 2006)
ISSN: 0315-162X [Print] Canada |
PMID | 16541480
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- Lipoproteins
- Lipoproteins, HDL
- Lipoproteins, LDL
- Triglycerides
- Tumor Necrosis Factor-alpha
- Cholesterol
- Infliximab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(pharmacology, therapeutic use)
- Antirheumatic Agents
(pharmacology, therapeutic use)
- Arthritis, Rheumatoid
(blood, drug therapy, physiopathology)
- Cholesterol
(blood)
- Endothelium, Vascular
(physiopathology)
- Female
- Humans
- Infliximab
- Lipoproteins
(blood)
- Lipoproteins, HDL
(blood)
- Lipoproteins, LDL
(blood)
- Longitudinal Studies
- Male
- Middle Aged
- Spondylitis, Ankylosing
(blood, drug therapy, physiopathology)
- Triglycerides
(blood)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|